A key issue in immuno-oncology is how to optimize and combine antibody therapies for improved efficacy. In this issue of Immunity, Buchan et al. (2018) reveal the importance of antibody Fc region, Fc receptor availability, and sequence of administration for optimal cancer therapy with antibodies targeting the co-stimulatory receptor 4-1BB.

中文翻译：

---

Fc工程化的抗4-1BB抗体包装了一两个拳头

免疫肿瘤学的关键问题是如何优化和结合抗体疗法以提高疗效。在本期《免疫》中，Buchan等人。（2018）揭示了抗体Fc区，Fc受体的可用性以及针对靶向共刺激受体4-1BB的抗体进行最佳癌症治疗的给药顺序的重要性。